Rexahn Pharmaceuticals to Present at the Roth Capital Partners 23rd Annual OC Growth Stock Conference Mar 14, 2011
Rexahn Pharmaceuticals Granted European Patent for New Quinoxalinyl-piperazine Compounds Feb 28, 2011
Teva Pharmaceutical Increases Its Investment in Rexahn for the Continued Research and Development of the Pre-Clinical Anti-Cancer Compound, RX-3117 Jan 20, 2011
Rexahn Pharmaceuticals Presents Serdaxin Phase IIa Clinical Data at the American College of Neuropsychopharmacologists Annual Meeting Dec 8, 2010
Rexahn Pharmaceuticals Announces Publication of New Preclinical Research Data for Novel Anticancer Compounds Nov 8, 2010
